Joseph Stringer
Stock Analyst at Needham
(4.88)
# 346
Out of 4,676 analysts
628
Total ratings
49.2%
Success rate
25.7%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintained: Hold | n/a | $158.83 | - | 44 | Aug 19, 2026 | |
| PLRX Pliant Therapeutics | Maintained: Hold | n/a | $1.19 | - | 34 | Aug 12, 2026 | |
| ANNX Annexon | Maintained: Buy | $25 | $5.15 | +385.44% | 39 | Aug 12, 2026 | |
| STTK Shattuck Labs | Maintained: Buy | $17 | $8.06 | +110.92% | 6 | Aug 11, 2026 | |
| VIR Vir Biotechnology | Reiterated: Buy | $18 | $10.71 | +68.07% | 47 | Aug 6, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $110 | $61.09 | +80.06% | 42 | Aug 6, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $35 | $10.11 | +246.19% | 7 | Aug 6, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $170 | $148.77 | +14.27% | 31 | Aug 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Hold | n/a | $552.85 | - | 33 | Aug 4, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $130 | $113.35 | +14.69% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $33.46 | +19.55% | 46 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $510 → $357 | $240.08 | +48.70% | 48 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $22 | $8.80 | +150.00% | 75 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $86 | $63.57 | +35.28% | 44 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.34 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.82 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.03 | n/a | 13 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $30.57 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $153.37 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $60.90 | n/a | 2 | Apr 28, 2021 |
Moderna
Aug 19, 2026
Maintained: Hold
Price Target: n/a
Current: $158.83
Upside: -
Pliant Therapeutics
Aug 12, 2026
Maintained: Hold
Price Target: n/a
Current: $1.19
Upside: -
Annexon
Aug 12, 2026
Maintained: Buy
Price Target: $25
Current: $5.15
Upside: +385.44%
Shattuck Labs
Aug 11, 2026
Maintained: Buy
Price Target: $17
Current: $8.06
Upside: +110.92%
Vir Biotechnology
Aug 6, 2026
Reiterated: Buy
Price Target: $18
Current: $10.71
Upside: +68.07%
Vaxcyte
Aug 6, 2026
Reiterated: Buy
Price Target: $110
Current: $61.09
Upside: +80.06%
BioAge Labs
Aug 6, 2026
Maintained: Buy
Price Target: $35
Current: $10.11
Upside: +246.19%
Gilead Sciences
Aug 5, 2026
Reiterated: Buy
Price Target: $170
Current: $148.77
Upside: +14.27%
Vertex Pharmaceuticals
Aug 4, 2026
Maintained: Hold
Price Target: n/a
Current: $552.85
Upside: -
Rhythm Pharmaceuticals
Aug 4, 2026
Maintained: Buy
Price Target: $130
Current: $113.35
Upside: +14.69%
Aug 4, 2026
Maintained: Buy
Price Target: $40
Current: $33.46
Upside: +19.55%
Jul 30, 2026
Maintained: Buy
Price Target: $510 → $357
Current: $240.08
Upside: +48.70%
Jul 30, 2026
Maintained: Buy
Price Target: $28 → $22
Current: $8.80
Upside: +150.00%
Jul 29, 2026
Maintained: Buy
Price Target: $86
Current: $63.57
Upside: +35.28%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $2.34
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $1.82
Upside: n/a
Dec 23, 2022
Rated: Hold
Price Target: n/a
Current: $17.03
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $30.57
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $153.37
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $60.90
Upside: n/a